At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living With Obesity or Overweight With Comorbidity
In Brief
A Phase 2 clinical trial evaluating AZD5004 and Placebo for Obesity or Overweight. Completed, enrolled 310 participants across 62 sites in 7 countries.
Detailed Summary
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male and female participants at least 18 years of age who are living with obesity (body mass index \[BMI\] ≥ 30 kg/m2), or overweight (BMI ≥ 27 kg/m2) who have at least 1 weight-related comorbidity
Study Details
Timeline
Interventions
AZD5004 film-coated tablet once daily during 36 weeks
Placebo matching AZD5004 film-coated tablet once daily during 36 weeks